Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1) Article

Web of Science: 000864724100388

Cited authors

  • Hess G, Thieblemont C, Clausen MR, Lugtenburg P, Balari SA, Zinzani PL, Wu J, Finn L, Vindelov SD, Fox CP

Authors

Publication date

  • 2022

International Standard Serial Number (ISSN)

  • 2296-5270

Number of pages

  • 2

Start page

  • 192

End page

  • 193

Volume

  • 45

Issue

  • SUPPL 2